These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

645 related articles for article (PubMed ID: 38565561)

  • 1. Adeno-associated virus as a delivery vector for gene therapy of human diseases.
    Wang JH; Gessler DJ; Zhan W; Gallagher TL; Gao G
    Signal Transduct Target Ther; 2024 Apr; 9(1):78. PubMed ID: 38565561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unravelling the essential elements for recombinant adeno-associated virus (rAAV) production in animal cell-based platforms.
    Catalán-Tatjer D; Tzimou K; Nielsen LK; Lavado-García J
    Biotechnol Adv; 2024; 73():108370. PubMed ID: 38692443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cellular pathways of recombinant adeno-associated virus production for gene therapy.
    Sha S; Maloney AJ; Katsikis G; Nguyen TNT; Neufeld C; Wolfrum J; Barone PW; Springs SL; Manalis SR; Sinskey AJ; Braatz RD
    Biotechnol Adv; 2021; 49():107764. PubMed ID: 33957276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The state of technological advancement to address challenges in the manufacture of rAAV gene therapies.
    Destro F; Wu W; Srinivasan P; Joseph J; Bal V; Neufeld C; Wolfrum JM; Manalis SR; Sinskey AJ; Springs SL; Barone PW; Braatz RD
    Biotechnol Adv; 2024 Nov; 76():108433. PubMed ID: 39168354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. rAAV immunogenicity, toxicity, and durability in 255 clinical trials: A meta-analysis.
    Shen W; Liu S; Ou L
    Front Immunol; 2022; 13():1001263. PubMed ID: 36389770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adeno-Associated Virus Engineering and Load Strategy for Tropism Modification, Immune Evasion and Enhanced Transgene Expression.
    Zhou X; Liu J; Xiao S; Liang X; Li Y; Mo F; Xin X; Yang Y; Gao C
    Int J Nanomedicine; 2024; 19():7691-7708. PubMed ID: 39099791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adeno-associated virus vectorology, manufacturing, and clinical applications.
    Grieger JC; Samulski RJ
    Methods Enzymol; 2012; 507():229-54. PubMed ID: 22365777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utilizing adeno-associated virus as a vector in treating genetic disorders or human cancers.
    Shih FH; Chang HH; Wang YC
    IUBMB Life; 2024 Dec; 76(12):1000-1010. PubMed ID: 38970351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expressing Transgenes That Exceed the Packaging Capacity of Adeno-Associated Virus Capsids.
    Chamberlain K; Riyad JM; Weber T
    Hum Gene Ther Methods; 2016 Feb; 27(1):1-12. PubMed ID: 26757051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays.
    Buck TM; Wijnholds J
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32545533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adeno-Associated Virus (AAV) Gene Delivery: Dissecting Molecular Interactions upon Cell Entry.
    Large EE; Silveria MA; Zane GM; Weerakoon O; Chapman MS
    Viruses; 2021 Jul; 13(7):. PubMed ID: 34372542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Understanding AAV vector immunogenicity: from particle to patient.
    Dhungel BP; Winburn I; Pereira CDF; Huang K; Chhabra A; Rasko JEJ
    Theranostics; 2024; 14(3):1260-1288. PubMed ID: 38323309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Designing and optimizing AAV-mediated gene therapy for neurodegenerative diseases: from bench to bedside.
    Xu L; Yao S; Ding YE; Xie M; Feng D; Sha P; Tan L; Bei F; Yao Y
    J Transl Med; 2024 Sep; 22(1):866. PubMed ID: 39334366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular design for recombinant adeno-associated virus (rAAV) vector production.
    Aponte-Ubillus JJ; Barajas D; Peltier J; Bardliving C; Shamlou P; Gold D
    Appl Microbiol Biotechnol; 2018 Feb; 102(3):1045-1054. PubMed ID: 29204900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Future of rAAV Gene Therapy: Platform for RNAi, Gene Editing, and Beyond.
    Valdmanis PN; Kay MA
    Hum Gene Ther; 2017 Apr; 28(4):361-372. PubMed ID: 28073291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Recombinant adeno-associated virus vector related impurities].
    Diao Y; Wang Q; Xiao W; Xu R
    Sheng Wu Gong Cheng Xue Bao; 2011 May; 27(5):717-23. PubMed ID: 21845838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of AAV Capsid-Specific T-Cell Responses on Design and Outcome of Clinical Gene Transfer Trials with Recombinant Adeno-Associated Viral Vectors: An Evolving Controversy.
    Ertl HCJ; High KA
    Hum Gene Ther; 2017 Apr; 28(4):328-337. PubMed ID: 28042943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Popularizing Recombinant Baculovirus-derived OneBac System for Laboratory Production of all Recombinant Adeno-associated Virus Vector Serotypes.
    Wu Y; Han Z; Duan M; Jiang L; Tian T; Jin D; Wang Q; Xu F
    Curr Gene Ther; 2021; 21(2):167-176. PubMed ID: 33461466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Critical challenges and advances in recombinant adeno-associated virus (rAAV) biomanufacturing.
    Fu Q; Polanco A; Lee YS; Yoon S
    Biotechnol Bioeng; 2023 Sep; 120(9):2601-2621. PubMed ID: 37126355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delivering Transgenic DNA Exceeding the Carrying Capacity of AAV Vectors.
    Hirsch ML; Wolf SJ; Samulski RJ
    Methods Mol Biol; 2016; 1382():21-39. PubMed ID: 26611576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.